Probabilistic Sensitivity Analyses With 1000 Iterations^*

Strategy	Median Discounted Incremental Life-Years per Person (95% CI) vs. Referent Strategy	Median Discounted Cost per Life-Year Gained (95% CI) vs. Referent Strategy, $
Amsterdam/IHC	0.021 (0.003–0.066)	38 200 (18 000–84 100)
Bethesda/IHC	0.088 (0.018–0.189)	33 300 (16 200–64 000)
PREMM/IHC	0.081 (0.015–0.182)	35 800 (17 200–71 600)
MMRpredict/IHC	0.063 (0.013–0.138)	32 600 (15 900–62 400)
MMRpro/IHC	0.081 (0.015–0.175)	32 500 (15 700–63 700)
Amsterdam/germline	0.026 (0.004–0.081)	37 900 (18 300–83 100)
Bethesda/germline	0.107 (0.022–0.233)	36 300 (17 800–69 400)
PREMM/germline	0.098 (0.018–0.220)	39 900 (19 500–85 100)
MMRpredict/germline	0.077 (0.015–0.169)	34 200 (16 700–65 000)
MMRpro/germline	0.098 (0.018–0.214)	34 500 (16 400–68 800)
IHC	0.219 (0.135–0.310)	40 500 (19 200–78 900)
IHC with BRAF testing	0.219 (0.135–0.308)	39 500 (18 900–77 000)
MSI	0.226 (0.142–0.319)	47 500 (22 900–98 600)
MSI plus IHC	0.259 (0.164–0.362)	53 200 (26 000–110 900)
MSI plus IHC with BRAF testing	0.259 (0.164–0.362)	52 300 (25 800–108 000)
Up-front germline testing	0.293 (0.186–0.410)	81 100 (37 800–201 000)

IHC = immunohistochemistry; MSI = microsatellite instability.

^*Assumes β distribution for application rate of clinical criteria strategies, with a median of 0.5 and range of 0 –1.